肿瘤细胞治疗研究
英文原题：Chimeric antigen receptor T-cell therapy: challenges and opportunities in lung cancer.
Chimeric antigen receptor T-cell therapy: challenges and opportunities in lung cancer.
嵌合抗原受体（CAR）T细胞疗法已经彻底改变了血液系统恶性肿瘤治疗的范式，推动了越来越多的基础研究和临床试验，这些研究和试验旨在通过基因工程改造T细胞来治疗实体瘤。
嵌合抗原受体（CAR）T细胞疗法已经彻底改变了血液系统恶性肿瘤治疗的范式，推动了越来越多的基础研究和临床试验，这些研究和试验旨在通过基因工程改造T细胞来治疗实体瘤。基于靶向Mesothelin、CEA、EGFR、EGFR、MUC1、DLL3以及新兴新靶点的抗体的CAR T细胞疗法为肺癌患者提供了有希望的疗效。然而，由于物理和免疫屏障、抗原逃逸和异质性、靶向非肿瘤毒性以及许多其他原因，CAR T细胞疗法针对肺癌的临床应用仍然有限。了解CAR结构的演变、制造CAR T细胞的通用要求以及肺部肿瘤免疫学与CAR T细胞之间的相互作用，将改善这种治疗方式在肺癌中的临床转化。在这篇综述中，我们系统总结了CAR T细胞疗法在肺癌中的最新进展，重点关注CAR结构、靶抗原、挑战以及相应的新策略。
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the paradigm in hematological malignancies treatment, driving an ever-expanding number of basic research and clinical trials of genetically engineering T cells to treat solid tumors. CAR T-cell therapies based on the antibodies targeting Mesothelin, CEA, EGFR, EGFR, MUC1, DLL3, and emerging novel targets provide promising efficacy for lung cancer patients. However, clinical application of CAR T-cell therapy against lung cancer remains limited on account of physical and immune barriers, antigen escape and heterogeneity, on-target off-tumor toxicity, and many other reasons. Understanding the evolution of CAR structure and the generalizable requirements for manufacturing CAR T cells as well as the interplay between lung tumor immunology and CAR T cells will improve clinical translation of this therapeutic modality in lung cancer. In this review, we systematically summarize the latest advances in CAR T-cell therapy in lung cancer, focusing on the CAR structure, target antigens, challenges, and corresponding new strategies.
MEMBER ACCOUNT
登录成功会直接打开下一页。
